NCT04059523View on ClinicalTrials.gov

MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

June 27, 2019

Primary Completion Date

February 6, 2020

Study Completion Date

February 6, 2020

Conditions
Acne Vulgaris
Interventions
DRUG

S6G5T-3

once daily

DRUG

Retin-A® 0.1% Cream

once daily

Trial Locations (2)

77845

J&S Studies, Inc, College Station

78759

DermResearch, Inc., Austin

All Listed Sponsors
lead

Sol-Gel Technologies, Ltd.

INDUSTRY

NCT04059523 - MUSE Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3 | Biotech Hunter | Biotech Hunter